+ All Categories
Home > Documents > NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008...

NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008...

Date post: 16-Dec-2015
Category:
Upload: cassandra-hubbard
View: 214 times
Download: 0 times
Share this document with a friend
Popular Tags:
21
NIH PUBLIC ACCESS POLICY NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental Department of Pharmacology and Experimental Neuroscience Neuroscience University of Nebraska Medical Center University of Nebraska Medical Center
Transcript
Page 1: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH PUBLIC ACCESS POLICYNIH PUBLIC ACCESS POLICY(Division G, Title II, Section 218 of PL110-161)(Division G, Title II, Section 218 of PL110-161)

Effective April 7, 2008Effective April 7, 2008

Robin TaylorDepartment of Pharmacology and Experimental Department of Pharmacology and Experimental NeuroscienceNeuroscienceUniversity of Nebraska Medical CenterUniversity of Nebraska Medical Center

Page 2: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

To make published research funded by

NIH accessible to everyone (including

health care providers, patients, educators

and scientists), which helps advance

science and improve human health.

Goal of the NIH PolicyGoal of the NIH Policy

University of Nebraska Medical Center

Page 3: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Goals of this trainingGoals of this training

How to determine if published research needs to comply

University of Nebraska Medical Center

How to comply

How to find resources

Page 4: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

This Policy is

Mandatory

University of Nebraska Medical Center

Page 5: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Any peer-reviewed article that was accepted for

publication after April 7, 2008 and is

Directly funded by an NIH grant or cooperative agreement active in Fiscal Year 2008 (October 1, 2007- September 30, 2008) or beyond;

Directly funded by a contract signed on or after

April 7, 2008;

Directly funded by the NIH Intramural Program; or

If NIH pays your salary

What does this policy apply What does this policy apply to?to?

University of Nebraska Medical Center

Page 6: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Important Things to Important Things to RememberRemember

Compliance is not a factor in the evaluation of grant applications. Non-compliance will be addressed administratively and may delay or prevent awarding of funds.

University of Nebraska Medical Center

The NIH Public Access policy is a condition of award for all grants and cooperative agreements active in Fiscal Year 2008 (October 1, 2007- September 30, 2008) and beyond.

Principal Investigators and their institutions are responsible for ensuring all terms and conditions of awards are met, even if the PI is not an author.

Page 7: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

How to Comply – 3 StepsHow to Comply – 3 Steps

Step 1 – Address CopyrightStep 1 – Address Copyright

Before a publication agreement or similar copyright transfer agreement is signed make sure that the agreement allows the article to be submitted to NIH in accordance with the Public Access Policy.

University of Nebraska Medical Center

Page 8: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Method A: Publish in a journal that deposits all NIH-funded final published articles in PMC without author involvement.

Method B: Make arrangements to have a publisher deposit a specific final published article in PMC.

Method C: Deposit the final peer-reviewed manuscript in PMC yourself via the NIHMS.

Method D: Complete the submission process for a final peer-reviewed manuscript that the publisher has deposited via the NIHMS.

University of Nebraska Medical Center

Step 2 – Deposit Paper after Step 2 – Deposit Paper after Acceptance for PublicationAcceptance for Publication

Page 9: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Step 3 - CiteStep 3 - Cite

As of May 25, 2008, articles cited in NIH applications, proposals and progress reports that fall under the Policy and authored or co-authored by the PI include evidence of compliance - PubMed Central ID reference number.

PubMed Central (PMCID) - electronic archive of full-text journal articles

PubMed (PMID) - database of bibliographic references

Only PMCID (or *temporary) numbers/statements meet the NIH Public Access requirement

University of Nebraska Medical Center

Page 10: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Author submitted manuscript: *temporary number

Reynolds, A.D., Stone, D.K., Hutter, J.A.L., Benner, E.J., Mosley, R.L., and Gendelman, H.E. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J. Immunol. 2009. In press. NIHMSID: NIHMS167968

University of Nebraska Medical Center

Author submitted manuscript: PMCID

Reynolds, A.D., Stone, D.K., Hutter, J.A.L., Benner, E.J., Mosley, R.L., and Gendelman, H.E. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J. Immunol. 2010 Mar 1;184(5):2261-71. PMCID: PMC2824790

How to cite to meet compliance:How to cite to meet compliance:

Journal submitted article: *temporary statement

Nowacek, A., McMillian, J., Miller, R., Anderson, A., Rabinow, B., Gendelman, H.E. J. Neuroimmuno Pharmacol. In Press.

PMC Journal-In Process

Page 11: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Publication did not use NIH fundsLi, Y., Bronich, T.K., Chelushkin, P.S., Kabanov, A.V. (2008) Dynamic Properties of Block Ionomer Complexes with Polyion Complex Cores. Macromolecules, 41, 5863-5868. No NIH funds

University of Nebraska Medical Center

How to cite an article that How to cite an article that does not does not need to comply:need to comply:

Publication accepted prior to April 7, 2008Gorantla, S., Liu, J., Wang, T., Holguin, A., Sneller, H.M., Dou, H., Kipnis, J., Poluektova, L., Gendelman, H.E. Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis. Glia. 56(2):223-232; 2008. Accepted: 16 October 2007

Publication not peer reviewedNowacek, A. and Gendelman, H.E. Nanotechnology and drug delivery for the nervous system and its relevance for neuroAIDS. Neuroimmunity. In press 2010. Not peer reviewed

Page 12: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

How to manually submit to PubMed How to manually submit to PubMed Central:Central:

Use the NIH Manuscript Submission (NIHMS) system.

University of Nebraska Medical Center

1. Deposit the manuscript files in the NIHMS system.

2. Indicate the NIH award(s) to which the article is

related: Every year of the award is listed. Only one year needs to

be selected.3. After the NIHMS converts the deposited files to a

standard PubMed Central (PMC) format, the PI will receive an e-mail from NIHMS to approve the PMC formatted article for release.

NIHMS temporary number can only be used be for

three months after date of publication (NOT-OD-09-

136).

Page 13: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

What you need to Submit:What you need to Submit:PI’s eRA common user name and password or your own

“myNCBI” login

Files (final peer reviewed)

• Text of manuscript

• Figures

• Tables

• Supplementary information

Types of files: any type that is acceptable to a journal can be submitted.

Note: Files can be uploaded separately or as one document. Grant information

• Usually found in the acknowledgement section of manuscript.

University of Nebraska Medical Center

Page 14: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Disclaimer/AcknowledgementDisclaimer/AcknowledgementJournals that do not automatically upload a manuscript may require a disclaimer or acknowledgement added to the manuscript. Check journal guidelines.

Journal of Neuroimmune Pharmacology - “The original publication is available at springerlink.com.”

The Journal of Immunology - "This is an author-produced version of a manuscript accepted for publication in The Journal of Immunology (The JI). The American Association of Immunologists, Inc. (AAI), publisher of The JI, holds the copyright to this manuscript. This version of the manuscript has not yet been copyedited or subjected to editorial proofreading by The JI; hence, it may differ from the final version published in The JI (online and in print). AAI (The JI) is not liable for errors or omissions in this author-produced version of the manuscript or in any version derived from it by the U.S. National Institutes of Health or any other third party. The final, citable version of record can be found at www.jimmunol.org."

University of Nebraska Medical Center

Page 15: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

NIH Manuscript Submission NIH Manuscript Submission SystemSystem

http://www.nihms.nih.gov/

University of Nebraska Medical Center

Page 16: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Embargo InformationEmbargo Information

Journals can require that an article not be made available (embargo) until after a certain time period.

1. NIH policy requires articles to be made available within 12 months of publication

Embargo dates are listed on the1. NIH Public Access Journal page 2. Journals’ web sites under NIH Public Access Policy or

Copyright/license information

University of Nebraska Medical Center

Page 17: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

References and LinksReferences and LinksPubMed Central

http://www.pubmedcentral.nih.gov/Help: [email protected]

NIH Manuscript Submission Systemhttp://www.nihms.nih.gov/Tutorials: http://www.nihms.nih.gov/web-help/

Public Access Frequently Asked Questionshttp://publicaccess.nih.gov/FAQ.htm#contentPMC Demo:

http://www.ncbi.nlm.nih.gov/education/pmc

University of Nebraska Medical Center

Page 18: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

References and LinksReferences and LinksPMID : PMCID Converter

http://www.ncbi.nlm.nih.gov/sites/pmctopmid

Journals that submit articles to PubMed Centralhttp://publicaccess.nih.gov/submit_process_journals.htm

Publishers that submit articles to PubMed Centralhttp://publicaccess.nih.gov/

select_deposit_publishers.htm

University of Nebraska Medical Center

McGoogan Libraryhttp://www.unmc.edu/

library/

Favorite Favorite SiteSite

Page 19: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Goals of this trainingGoals of this training

How to determine if published research

needs to comply

How to comply

How to find resources

University of Nebraska Medical Center

Page 20: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

Thank you!Thank you!

Kim Laursen and the UNMC Research Users Group

Howard Gendelman, M.D. and Julie DitterDepartment of Pharmacology and Experimental Neuroscience

University of Nebraska Medical Center

Page 21: NIH PUBLIC ACCESS POLICY (Division G, Title II, Section 218 of PL110-161) Effective April 7, 2008 Robin Taylor Department of Pharmacology and Experimental.

NIH Public Access Policy

University of Nebraska Medical CenterUniversity of Nebraska Medical Center


Recommended